Introduction. COVID‐19 has been associated with the overactivation of the immune system;
interleukin‐6 (IL‐6) seems to have a key role, which made its moderation to be proposed as …

Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected
COVID-19 patients. The objective is to present our experience of tocilizumab use in patients …

The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill
COVID-19: Single Centered Experience Case Page 1 319 Acta Med Indones - Indones J Intern …

Introduction In COVID 19, an aggressive inflammatory response called cytokine release
storm has been described. It is mainly mediated by the activation of Interleukin 6 (IL-6) and …

Tocilizumab in patients with severe COVID-19 pneumonia in Veracruz, Mexico Page 1 Submit
Manuscript | http://medcraveonline.com objective which was to improve the mortality rate. It also …

Recently it has been demonstrated the clinical effectiveness of tocilizumab (TCZ) associated
with systemic steroids for the treatment of severe SARS-CoV-2 pneumonia with rapid …

Methods Multicenter, retrospective cohort study including patients> 18 years hospitalized
between 7/1/2021-8/1/2022 with confirmed COVID-19, with 5, 6 and 7 points of WHO Ordinal …

BACKGROUND Coronavirus disease 2019 triggers a cytokine storm resulting in high
mortality. A key player in this cytokine storm has been considered as interleukin-6 …

Resumen MARTINEZ-GUERRA, Bernardo A. et al. Effect of Tocilizumab in Mortality among
Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center …

Objectives To assess the effectiveness and safety of tocilizumab, a humanised anti‐
interleukin‐6 receptor antibody, in the treatment of critical or severe coronavirus disease …